

### **Product Information**

Acrylamide/Bis-acrylamide solution 30% (19:1)

Catalogue Number: GBPAB01/01F

## **General Information**

The Acrylamide/Bis-acrylamide Solution 30% (19:1) is a pre-mixed, ready-to-use solution specifically designed for SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis), enabling efficient protein separation with reduced handling hazards. This formulation minimizes user exposure to acrylamide powders, offering a safe and consistent solution ideal for research and diagnostic labs.

This solution contains a 30% blend of acrylamide and bis-acrylamide at a precise 19:1 ratio, optimized for creating a strong yet flexible gel matrix suitable for protein and nucleic acid separation. Acrylamide polymerizes into long chains, cross-linked by bis-acrylamide, creating a stable gel matrix essential for effective molecular separation. This solution meets high purity standards, free from DNase and RNase contaminants, ensuring reliable performance in PAGE applications.

# **Product Specification**

Appearance : Clear, colorless solution

Storage & Shelf Life : Store at +2°C to +8°C protected from light and use within 12 months.

Shipping Conditions : Frozen (Dry Ice)

Sterility : No bacterial or fungal growth (14 days at USP specifications)

DNase & RNase : None detected

#### Formulation

Components	Concentration g/L
Acrylamide	285
N,N-Methylene Bis-acrylamide	15

For Research Use Only

# Need help?

If you have any further queries, please feel free to email our cell culture specialists at info@genexisbiotech.com

Disclaimer: User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related Products are not intended for human or animal diagnostic or therapeutic use but for laboratory, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.